CeQur Announces $100 Million in Financing for Insulin Infusion Device
Switzerland-based diabetes device maker CeQur has secured $100 million in a Series C financing that will support preparation of the 2016 launch of PaQ, the company’s second-generation three-day insulin infusion device.
The financing will fund clinical and regulatory activities, manufacturing scale-up and commercial operations.
PaQ is patch-like device that offers an alternative to insulin injections for people with type 2 diabetes.
CeQur says it will have completed three clinical studies among patients transferred from insulin injection therapy prior to the product’s launch. — Michael Cipriano